{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:53:55Z","timestamp":1794668035692,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We previously demonstrated that pretreatment with Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) \u2013mediated dopaminergic neurodegeneration. The use of GLP-1 or Exendin-4 for Parkinson\u2019s disease (PD) patients is limited by their short half-lives. The purpose of this study was to evaluate a new extended release Exendin-4 formulation, PT302, in a rat model of PD. Subcutaneous administration of PT302 resulted in sustained elevations of Exendin-4 in plasma for &gt;20 days in adult rats. To define an efficacious dose within this range, rats were administered PT302 once every 2 weeks either before or following the unilaterally 6-hydroxydopamine lesioning. Pre- and post-treatment with PT302 significantly reduced methamphetamine\u2013induced rotation after lesioning. For animals given PT302 post lesion, blood and brain samples were collected on day 47 for measurements of plasma Exendin-4 levels and brain tyrosine hydroxylase immunoreactivity (TH-IR). PT302 significantly increased TH-IR in the lesioned substantia nigra and striatum. There was a significant correlation between plasma Exendin-4 levels and TH-IR in the substantia nigra and striatum on the lesioned side. Our data suggest that post-treatment with PT302 provides long-lasting Exendin-4 release and reduces neurodegeneration of nigrostriatal dopaminergic neurons in a 6-hydroxydopamine rat model of PD at a clinically relevant dose.<\/jats:p>","DOI":"10.1038\/s41598-018-28449-z","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T11:44:38Z","timestamp":1531223078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson\u2019s disease"],"prefix":"10.1038","volume":"8","author":[{"given":"Shuchun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Jin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Lecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Glotfelty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Hoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"28449_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes, O. B. & Storstein, A. Epidemiology of Parkinson\u2019s disease. J. Neural Transm. (Vienna.) 124, 901\u2013905 (2017).","journal-title":"J. Neural Transm. (Vienna.)"},{"key":"28449_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mds.25292","volume":"28","author":"SL Kowal","year":"2013","unstructured":"Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V. & Jain, A. The current and projected economic burden of Parkinson\u2019s disease in the United States. Mov Disord. 28, 311\u2013318 (2013).","journal-title":"Mov Disord."},{"key":"28449_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/mds.27063","volume":"33","author":"A Rossi","year":"2018","unstructured":"Rossi, A. et al. Projection of the prevalence of Parkinson\u2019s disease in the coming decades: Revisited. Mov Disord. 33, 156\u2013159 (2018).","journal-title":"Mov Disord."},{"key":"28449_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide, M. F. et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease. Prog. Neurobiol. 132, 96\u2013168 (2015).","journal-title":"Prog. Neurobiol."},{"key":"28449_CR5","first-page":"729194","volume":"2014","author":"P Zhang","year":"2014","unstructured":"Zhang, P. & Tian, B. Metabolic syndrome: an important risk factor for Parkinson\u2019s disease. Oxid. Med. Cell Longev. 2014, 729194 (2014).","journal-title":"Oxid. Med. Cell Longev."},{"key":"28449_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fnagi.2016.00065","volume":"8","author":"J Song","year":"2016","unstructured":"Song, J. & Kim, J. Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson\u2019s Disease. Front Aging Neurosci 8, 65 (2016).","journal-title":"Front Aging Neurosci"},{"key":"28449_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/ane.12793","volume":"136","author":"E De Pablo-Fernandez","year":"2017","unstructured":"De Pablo-Fernandez, E., Sierra-Hidalgo, F., Benito-Leon, J. & Bermejo-Pareja, F. Association between Parkinson\u2019s disease and diabetes: Data from NEDICES study. Acta Neurol. Scand. 136, 732\u2013736 (2017).","journal-title":"Acta Neurol. Scand."},{"key":"28449_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda, D. & Foltynie, T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. Drug Discov. Today 21, 802\u2013818 (2016).","journal-title":"Drug Discov. Today"},{"key":"28449_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/brain\/aws009","volume":"136","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos, I., Limousin, P., Lees, A. & Foltynie, T. Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection. Brain 136, 374\u2013384 (2013).","journal-title":"Brain"},{"key":"28449_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","volume":"118","author":"F Bassil","year":"2014","unstructured":"Bassil, F., Fernagut, P. O., Bezard, E. & Meissner, W. G. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog. Neurobiol. 118, 1\u201318 (2014).","journal-title":"Prog. Neurobiol."},{"key":"28449_CR11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2337\/dc06-2011","volume":"30","author":"G Hu","year":"2007","unstructured":"Hu, G., Jousilahti, P., Bidel, S., Antikainen, R. & Tuomilehto, J. Type 2 diabetes and the risk of Parkinson\u2019s disease. Diabetes Care 30, 842\u2013847 (2007).","journal-title":"Diabetes Care"},{"key":"28449_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2337\/dc10-1922","volume":"34","author":"Q Xu","year":"2011","unstructured":"Xu, Q. et al. Diabetes and risk of Parkinson\u2019s disease. Diabetes Care 34, 910\u2013915 (2011).","journal-title":"Diabetes Care"},{"key":"28449_CR13","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.2337\/dc08-0688","volume":"31","author":"JA Driver","year":"2008","unstructured":"Driver, J. A. et al. Prospective cohort study of type 2 diabetes and the risk of Parkinson\u2019s disease. Diabetes Care 31, 2003\u20132005 (2008).","journal-title":"Diabetes Care"},{"key":"28449_CR14","doi-asserted-by":"publisher","first-page":"R1082","DOI":"10.1152\/ajpregu.00449.2010","volume":"299","author":"JK Morris","year":"2010","unstructured":"Morris, J. K., Bomhoff, G. L., Stanford, J. A. & Geiger, P. C. Neurodegeneration in an animal model of Parkinson\u2019s disease is exacerbated by a high-fat diet. Am. J. Physiol Regul. Integr. Comp Physiol 299, R1082\u2013R1090 (2010).","journal-title":"Am. J. Physiol Regul. Integr. Comp Physiol"},{"key":"28449_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.expneurol.2011.06.005","volume":"231","author":"JK Morris","year":"2011","unstructured":"Morris, J. K. et al. Insulin resistance impairs nigrostriatal dopamine function. Exp. Neurol. 231, 171\u2013180 (2011).","journal-title":"Exp. Neurol."},{"key":"28449_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep29967","volume":"6","author":"G Perruolo","year":"2016","unstructured":"Perruolo, G. et al. Parkinson-like phenotype in insulin-resistant PED\/PEA-15 transgenic mice. Sci Rep 6, 29967 (2016).","journal-title":"Sci Rep"},{"key":"28449_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0301-0082(91)90015-S","volume":"36","author":"JW Unger","year":"1991","unstructured":"Unger, J. W., Livingston, J. N. & Moss, A. M. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog. Neurobiol. 36, 343\u2013362 (1991).","journal-title":"Prog. Neurobiol."},{"key":"28449_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/BF00313602","volume":"87","author":"I Moroo","year":"1994","unstructured":"Moroo, I. et al. Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson\u2019s disease. Acta Neuropathol. 87, 343\u2013348 (1994).","journal-title":"Acta Neuropathol."},{"key":"28449_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/jnc.13930","volume":"140","author":"KT Jones","year":"2017","unstructured":"Jones, K. T. et al. Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain. J. Neurochem. 140, 728\u2013740 (2017).","journal-title":"J. Neurochem."},{"key":"28449_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9543","volume":"6","author":"MA Stouffer","year":"2015","unstructured":"Stouffer, M. A. et al. Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nat. Commun. 6, 8543 (2015).","journal-title":"Nat. Commun."},{"key":"28449_CR21","doi-asserted-by":"crossref","unstructured":"Athauda, D. & Foltynie,T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson\u2019s disease. Neuropharmacology. In Press (2017).","DOI":"10.1016\/j.neuropharm.2017.09.023"},{"key":"28449_CR22","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1111\/j.1460-9568.1995.tb00650.x","volume":"7","author":"R Goke","year":"1995","unstructured":"Goke, R., Larsen, P. J., Mikkelsen, J. D. & Sheikh, S. P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci 7, 2294\u20132300 (1995).","journal-title":"Eur. J. Neurosci"},{"key":"28449_CR23","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","volume":"166","author":"I Salcedo","year":"2012","unstructured":"Salcedo, I., Tweedie, D., Li, Y. & Greig, N. H. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br. J. Pharmacol. 166, 1586\u20131599 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"28449_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1055\/s-2004-826162","volume":"36","author":"Y Yamada","year":"2004","unstructured":"Yamada, Y. & Seino, Y. Physiology of GIP\u2013a lesson from GIP receptor knockout mice. Horm. Metab Res. 36, 771\u2013774 (2004).","journal-title":"Horm. Metab Res."},{"key":"28449_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","volume":"403","author":"I Merchenthaler","year":"1999","unstructured":"Merchenthaler, I., Lane, M. & Shughrue, P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp Neurol. 403, 261\u2013280 (1999).","journal-title":"J. Comp Neurol."},{"key":"28449_CR26","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0806720106","volume":"106","author":"Y Li","year":"2009","unstructured":"Li, Y. et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci USA 106, 1285\u20131290 (2009).","journal-title":"Proc. Natl. Acad. Sci USA"},{"key":"28449_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-5-19","volume":"5","author":"A Harkavyi","year":"2008","unstructured":"Harkavyi, A. et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease. J. Neuroinflammation. 5, 19 (2008).","journal-title":"J. Neuroinflammation."},{"key":"28449_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.02.013","volume":"117","author":"J Jalewa","year":"2017","unstructured":"Jalewa, J., Sharma, M. K., Gengler, S. & Holscher, C. A novel GLP-1\/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson\u2019s disease. Neuropharmacology 117, 238\u2013248 (2017).","journal-title":"Neuropharmacology"},{"key":"28449_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ddr.1195","volume":"53","author":"D Parkes","year":"2001","unstructured":"Parkes, D. et al. Pharmacokinetic Actions of Exendin-4 in the Rat: Comparison With Glucagon-Like Peptide-1. Drug Dev. Res. 53, 260\u2013267 (2001).","journal-title":"Drug Dev. Res."},{"key":"28449_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell, J. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17, 819\u2013837 (2013).","journal-title":"Cell Metab"},{"key":"28449_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","volume":"18","author":"FK Knop","year":"2017","unstructured":"Knop, F. K., Bronden, A. & Vilsboll, T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert. Opin. Pharmacother. 18, 555\u2013571 (2017).","journal-title":"Expert. Opin. Pharmacother."},{"key":"28449_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos, I. et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease. J. Parkinsons. Dis. 4, 337\u2013344 (2014).","journal-title":"J. Parkinsons. Dis."},{"key":"28449_CR33","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jalz.2013.12.005","volume":"10","author":"T Foltynie","year":"2014","unstructured":"Foltynie, T. & Aviles-Olmos, I. Exenatide as a potential treatment for patients with Parkinson\u2019s disease: first steps into the clinic. Alzheimers. Dement. 10, S38\u2013S46 (2014).","journal-title":"Alzheimers. Dement."},{"key":"28449_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3233\/JPD-171192","volume":"7","author":"D Athauda","year":"2017","unstructured":"Athauda, D., Wyse, R., Brundin, P. & Foltynie, T. Is Exenatide a Treatment for Parkinson\u2019s Disease? J. Parkinsons. Dis. 7, 451\u2013458 (2017).","journal-title":"J. Parkinsons. Dis."},{"key":"28449_CR35","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664\u20131675 (2017).","journal-title":"Lancet"},{"key":"28449_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.clinthera.2013.12.002","volume":"36","author":"N Gu","year":"2014","unstructured":"Gu, N. et al. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study. Clin. Ther. 36, 101\u2013114 (2014).","journal-title":"Clin. Ther."},{"key":"28449_CR37","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1177\/0963689717721234","volume":"26","author":"DS Kim","year":"2017","unstructured":"Kim, D. S. et al. A New Treatment Strategy for Parkinson\u2019s Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway. Cell Transplant. 26, 1560\u20131571 (2017).","journal-title":"Cell Transplant."},{"key":"28449_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneurol.2017.140","volume":"13","author":"J Jankovic","year":"2017","unstructured":"Jankovic, J. Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease? Nat. Rev. Neurol. 13, 643\u2013644 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"28449_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DMSO.S126763","volume":"10","author":"H Courtney","year":"2017","unstructured":"Courtney, H., Nayar, R., Rajeswaran, C. & Jandhyala, R. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes Metab Syndr. Obes. 10, 79\u201387 (2017).","journal-title":"Diabetes Metab Syndr. Obes."},{"key":"28449_CR40","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10571-011-9671-8","volume":"31","author":"LA Greene","year":"2011","unstructured":"Greene, L. A., Levy, O. & Malagelada, C. Akt as a victim, villain and potential hero in Parkinson\u2019s disease pathophysiology and treatment. Cell Mol Neurobiol. 31, 969\u2013978 (2011).","journal-title":"Cell Mol Neurobiol."},{"key":"28449_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3892\/ijmm.2016.2833","volume":"39","author":"N Nakano","year":"2017","unstructured":"Nakano, N. et al. PI3K\/AKT signaling mediated by G proteincoupled receptors is involved in neurodegenerative Parkinson\u2019s disease (Review). Int. J. Mol Med. 39, 253\u2013260 (2017).","journal-title":"Int. J. Mol Med."},{"key":"28449_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuropharm.2014.01.039","volume":"80","author":"A Ciccarelli","year":"2014","unstructured":"Ciccarelli, A. & Giustetto, M. Role of ERK signaling in activity-dependent modifications of histone proteins. Neuropharmacology 80, 34\u201344 (2014).","journal-title":"Neuropharmacology"},{"key":"28449_CR43","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1471-4159.2010.06731.x","volume":"113","author":"Y Li","year":"2010","unstructured":"Li, Y., Tweedie, D., Mattson, M. P., Holloway, H. W. & Greig, N. H. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 113, 1621\u20131631 (2010).","journal-title":"J. Neurochem."},{"key":"28449_CR44","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer, W. & Przedborski, S. Parkinson\u2019s disease: mechanisms and models. Neuron 39, 889\u2013909 (2003).","journal-title":"Neuron"},{"key":"28449_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1677\/JOE-09-0132","volume":"202","author":"S Kim","year":"2009","unstructured":"Kim, S., Moon, M. & Park, S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease. J. Endocrinol. 202, 431\u2013439 (2009).","journal-title":"J. Endocrinol."},{"key":"28449_CR46","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","volume":"86","author":"G Bertilsson","year":"2008","unstructured":"Bertilsson, G. et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease. J. Neurosci Res. 86, 326\u2013338 (2008).","journal-title":"J. Neurosci Res."},{"key":"28449_CR47","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.2042-7158.2011.01394.x","volume":"64","author":"A Abuirmeileh","year":"2012","unstructured":"Abuirmeileh, A. et al. Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat. J. Pharm. Pharmacol. 64, 637\u2013643 (2012).","journal-title":"J. Pharm. Pharmacol."},{"key":"28449_CR48","first-page":"407152","volume":"2013","author":"A Harkavyi","year":"2013","unstructured":"Harkavyi, A., Rampersaud, N. & Whitton, P. S. Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D3 Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra. J. Neurodegener. Dis. 2013, 407152 (2013).","journal-title":"J. Neurodegener. Dis."},{"key":"28449_CR49","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.brainres.2016.05.038","volume":"1646","author":"HH Hansen","year":"2016","unstructured":"Hansen, H. H. et al. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson\u2019s disease. Brain Res. 1646, 354\u2013365 (2016).","journal-title":"Brain Res."},{"key":"28449_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","volume":"303","author":"W Liu","year":"2015","unstructured":"Liu, W. et al. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Neuroscience 303, 42\u201350 (2015).","journal-title":"Neuroscience"},{"key":"28449_CR51","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/brain\/awx044","volume":"140","author":"F Bassil","year":"2017","unstructured":"Bassil, F. et al. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain 140, 1420\u20131436 (2017).","journal-title":"Brain"},{"key":"28449_CR52","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1001\/archneur.1990.00530120034007","volume":"47","author":"KL Leenders","year":"1990","unstructured":"Leenders, K. L. et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson\u2019s disease. Arch. Neurol. 47, 1290\u20131298 (1990).","journal-title":"Arch. Neurol."},{"key":"28449_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.brainres.2010.11.006","volume":"1370","author":"AD Cohen","year":"2011","unstructured":"Cohen, A. D., Zigmond, M. J. & Smith, A. D. Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration. Brain Res. 1370, 80\u201388 (2011).","journal-title":"Brain Res."},{"key":"28449_CR54","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/ejn.12459","volume":"39","author":"SR Stott","year":"2014","unstructured":"Stott, S. R. & Barker, R. A. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson\u2019s disease. Eur. J. Neurosci 39, 1042\u20131056 (2014).","journal-title":"Eur. J. Neurosci"},{"issue":"Suppl 1","key":"28449_CR55","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.1016\/S1353-8020(11)70057-8","volume":"18","author":"V Jackson-Lewis","year":"2012","unstructured":"Jackson-Lewis, V., Blesa, J. & Przedborski, S. Animal models of Parkinson\u2019s disease. Parkinsonism. Relat Disord. 18(Suppl 1), S183\u2013S185 (2012).","journal-title":"Parkinsonism. Relat Disord."},{"key":"28449_CR56","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3233\/JPD-160881","volume":"6","author":"Z Kurowska","year":"2016","unstructured":"Kurowska, Z. et al. Is Axonal Degeneration a Key Early Event in Parkinson\u2019s Disease? J. Parkinsons. Dis. 6, 703\u2013707 (2016).","journal-title":"J. Parkinsons. Dis."},{"issue":"Suppl 2","key":"28449_CR57","first-page":"S16","volume":"64","author":"P Jenner","year":"2008","unstructured":"Jenner, P. Functional models of Parkinson\u2019s disease: a valuable tool in the development of novel therapies. Ann. Neurol. 64(Suppl 2), S16\u2013S29 (2008).","journal-title":"Ann. Neurol."},{"key":"28449_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","volume":"18","author":"AJ Kastin","year":"2002","unstructured":"Kastin, A. J., Akerstrom, V. & Pan, W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol Neurosci 18, 7\u201314 (2002).","journal-title":"J. Mol Neurosci"},{"key":"28449_CR59","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","volume":"27","author":"AJ Kastin","year":"2003","unstructured":"Kastin, A. J. & Akerstrom, V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat Metab Disord. 27, 313\u2013318 (2003).","journal-title":"Int. J. Obes. Relat Metab Disord."},{"key":"28449_CR60","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J. & Nauck, M. A. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes. Metab 19, 336\u2013347 (2017).","journal-title":"Diabetes Obes. Metab"},{"key":"28449_CR61","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/17425255.2018.1420160","volume":"14","author":"VM Molina","year":"2018","unstructured":"Molina, V. M., Munoz-Garach, A. & Tinahones, F. J. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. Expert. Opin. Drug Metab Toxicol. 14, 207\u2013217 (2018).","journal-title":"Expert. Opin. Drug Metab Toxicol."},{"key":"28449_CR62","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00592-017-1054-2","volume":"54","author":"M Monami","year":"2017","unstructured":"Monami, M. et al. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetol. 54, 1101\u20131114 (2017).","journal-title":"Acta Diabetol."},{"key":"28449_CR63","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos, I. et al. Exenatide and the treatment of patients with Parkinson\u2019s disease. J. Clin. Invest 123, 2730\u20132736 (2013).","journal-title":"J. Clin. Invest"},{"key":"28449_CR64","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0006-8993(93)90576-9","volume":"626","author":"JL Hudson","year":"1993","unstructured":"Hudson, J. L. et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626, 167\u2013174 (1993).","journal-title":"Brain Res."},{"key":"28449_CR65","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11892-016-0728-4","volume":"16","author":"H Peng","year":"2016","unstructured":"Peng, H., Want, L. L. & Aroda, V. R. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. Curr. Diab. Rep 16, 44 (2016).","journal-title":"Curr. Diab. Rep"},{"key":"28449_CR66","doi-asserted-by":"crossref","unstructured":"Luo, Y., Hoffer, B. J., & Wang, Y. Rotation, Drug-induced in Encyclopedia of Movement Disorders (eds. Kompoliti, K. & Verhagen Metman, L.) 49\u201351 (Academic Press, Oxford, 2010).","DOI":"10.1016\/B978-0-12-374105-9.00281-1"},{"key":"28449_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-13-120","volume":"13","author":"LH Yin","year":"2012","unstructured":"Yin, L. H. et al. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson\u2019s disease. BMC. Neurosci. 13, 120 (2012).","journal-title":"BMC. Neurosci."}],"updated-by":[{"DOI":"10.1038\/s41598-018-31455-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28449-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28449-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28449-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T02:11:11Z","timestamp":1720404671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28449-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["28449"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-28449-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.-K. Kim, D.-S. Kim and H.-I. Choi are employees of Peptron Inc. The Intramural Research Program of the National Institute on Aging, NIH, and Peptron Inc. have a Cooperative Research and Development Agreement to develop exendin-4 (exenatide) as a treatment strategy for neurodegenerative disorders for which NIA and Peptron Inc. hold patent rights via the work of H.-K. Kim, D.-S. Kim, H.I.-Choi and N.H. Greig (NIH: Greig N.H. <i>et al<\/i>., U.S. Patents 8,278,272 and 8,853,160 (issued); joint Peptron\/NIH: Kim D.-S. <i>et al<\/i>., PCT\/US17\/57606 (pending)). N.H. Greig has assigned all patent rights to the NIH and US Government. All other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10722"}}